Taken together, these results indicated that the CDK4/RNF26/TSC1 axis regulates the anticancer efficacy of CDK4/6 inhibitors and mTOR inhibitors in ccRCC. The gene discussed is TSC1; the disease is nonpapillary renal cell carcinoma.